Lipid-lowering drug
Phase 3Small molecule
Lipid-lowering drug is one of 4 small molecule programs targeting Anti-inflammatory Therapy. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Anti-Inflammatory Therapy
#DrugCompanyPhaseTrials
1Colcrys
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Rayos
RRoxane Laboratories
Approved
Lipid-lowering drug
FFirst Affiliated Hospital of Wenzhou Medical University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Peripheral Neuropathy1 trial
The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy
Unknown status·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT06041399·1,400 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lipid-lowering drug. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details